JP2020526591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526591A5 JP2020526591A5 JP2020523041A JP2020523041A JP2020526591A5 JP 2020526591 A5 JP2020526591 A5 JP 2020526591A5 JP 2020523041 A JP2020523041 A JP 2020523041A JP 2020523041 A JP2020523041 A JP 2020523041A JP 2020526591 A5 JP2020526591 A5 JP 2020526591A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- compound
- disease
- compound according
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 206010027175 memory impairment Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 102100039883 DNA-directed RNA polymerase III subunit RPC5 Human genes 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 1
- 208000025967 Dissociative Identity disease Diseases 0.000 claims 1
- 101000669240 Homo sapiens DNA-directed RNA polymerase III subunit RPC5 Proteins 0.000 claims 1
- 208000030990 Impulse-control disease Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 102000003621 TRPC5 Human genes 0.000 claims 1
- 101150042815 TRPC5 gene Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000010457 affective process Effects 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 239000003048 aphrodisiac agent Substances 0.000 claims 1
- 230000002509 aphrodisiac effect Effects 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000005204 segregation Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 0 CC(C)N(c1c(C(N2CCCO)=O)[n](Cc(cc3)cc(F)c3F)c(-c3c(*CC4CC4)nccc3)n1)C2=O Chemical compound CC(C)N(c1c(C(N2CCCO)=O)[n](Cc(cc3)cc(F)c3F)c(-c3c(*CC4CC4)nccc3)n1)C2=O 0.000 description 1
- VENVUGFQRNLDEU-UHFFFAOYSA-N CC(C)N(c1c(C(N2CCCO)=O)[n](Cc3cc(F)cc(F)c3)c(-c(cccn3)c3OCC3CC3)n1)C2=O Chemical compound CC(C)N(c1c(C(N2CCCO)=O)[n](Cc3cc(F)cc(F)c3)c(-c(cccn3)c3OCC3CC3)n1)C2=O VENVUGFQRNLDEU-UHFFFAOYSA-N 0.000 description 1
- LXFRJYSKAMYIHV-UHFFFAOYSA-N CC(C)N(c1c(C(N2CCCO)=O)[n](Cc3ccc(C(F)(F)F)cc3)c(-c(cccn3)c3OCC3CC3)n1)C2=O Chemical compound CC(C)N(c1c(C(N2CCCO)=O)[n](Cc3ccc(C(F)(F)F)cc3)c(-c(cccn3)c3OCC3CC3)n1)C2=O LXFRJYSKAMYIHV-UHFFFAOYSA-N 0.000 description 1
- VHRRZQNQIMXDFL-UHFFFAOYSA-N CC(C)N(c1c(C(N2CCCO)=O)[n](Cc3ccc(C)cc3)c(-c(cccn3)c3OCC3CC3)n1)C2=O Chemical compound CC(C)N(c1c(C(N2CCCO)=O)[n](Cc3ccc(C)cc3)c(-c(cccn3)c3OCC3CC3)n1)C2=O VHRRZQNQIMXDFL-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17180721.7 | 2017-07-11 | ||
| EP17180721 | 2017-07-11 | ||
| PCT/EP2018/068366 WO2019011802A1 (en) | 2017-07-11 | 2018-07-06 | NEW SUBSTITUTED XANTHINE DERIVATIVES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526591A JP2020526591A (ja) | 2020-08-31 |
| JP2020526591A5 true JP2020526591A5 (https=) | 2021-08-12 |
| JP7114702B2 JP7114702B2 (ja) | 2022-08-08 |
Family
ID=59325162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523041A Active JP7114702B2 (ja) | 2017-07-11 | 2018-07-06 | 新規置換キサンチン誘導体 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US10329292B2 (https=) |
| EP (1) | EP3652176B1 (https=) |
| JP (1) | JP7114702B2 (https=) |
| KR (1) | KR102714554B1 (https=) |
| CN (1) | CN110997675B (https=) |
| AR (1) | AR112448A1 (https=) |
| AU (1) | AU2018299824B2 (https=) |
| CA (1) | CA3066922A1 (https=) |
| CL (1) | CL2020000056A1 (https=) |
| CO (1) | CO2019015102A2 (https=) |
| CY (1) | CY1125014T1 (https=) |
| DK (1) | DK3652176T3 (https=) |
| EA (1) | EA039526B1 (https=) |
| ES (1) | ES2903268T3 (https=) |
| HR (1) | HRP20220029T1 (https=) |
| HU (1) | HUE057600T2 (https=) |
| IL (1) | IL271799B (https=) |
| LT (1) | LT3652176T (https=) |
| MX (1) | MX394089B (https=) |
| MY (1) | MY200797A (https=) |
| PE (1) | PE20200861A1 (https=) |
| PH (1) | PH12020500079A1 (https=) |
| PL (1) | PL3652176T3 (https=) |
| PT (1) | PT3652176T (https=) |
| RS (1) | RS62826B1 (https=) |
| SA (1) | SA519410851B1 (https=) |
| SG (1) | SG11201912168TA (https=) |
| SI (1) | SI3652176T1 (https=) |
| SM (1) | SMT202200013T1 (https=) |
| TW (1) | TWI801398B (https=) |
| UA (1) | UA124793C2 (https=) |
| WO (1) | WO2019011802A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093084A1 (en) | 2018-03-05 | 2019-09-12 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
| US12291532B2 (en) | 2018-12-12 | 2025-05-06 | Boehringer Ingelheim International Gmbh | Substituted xanthines as modulators of TRPC5 activity |
| HUE064908T2 (hu) * | 2018-12-12 | 2024-04-28 | Boehringer Ingelheim Int | Szubsztituált xantinszármazékok |
| JP2022551580A (ja) * | 2019-10-04 | 2022-12-12 | ゴールドフィンチ バイオ，インク． | 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置 |
| WO2024153028A1 (zh) * | 2023-01-20 | 2024-07-25 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
| WO2024164818A1 (zh) | 2023-02-08 | 2024-08-15 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1368349B1 (de) * | 2001-02-24 | 2007-02-14 | Boehringer Ingelheim Pharma GmbH & Co.KG | Xanthinderivate, deren herstellung und deren verwendung als arzneimittel |
| US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| ATE496894T1 (de) * | 2006-07-14 | 2011-02-15 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2- |
| CN107082782B (zh) * | 2013-03-15 | 2020-03-20 | 海德拉生物科学有限责任公司 | 取代的黄嘌呤及其使用方法 |
| TWI676626B (zh) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | 抑制瞬時受體電位ａ１離子通道 |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| WO2016023830A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| JP6559228B2 (ja) | 2014-09-17 | 2019-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物 |
-
2018
- 2018-07-06 DK DK18735588.8T patent/DK3652176T3/da active
- 2018-07-06 HR HRP20220029TT patent/HRP20220029T1/hr unknown
- 2018-07-06 PE PE2019002691A patent/PE20200861A1/es unknown
- 2018-07-06 CN CN201880045961.0A patent/CN110997675B/zh active Active
- 2018-07-06 JP JP2020523041A patent/JP7114702B2/ja active Active
- 2018-07-06 KR KR1020207000260A patent/KR102714554B1/ko active Active
- 2018-07-06 PL PL18735588T patent/PL3652176T3/pl unknown
- 2018-07-06 LT LTEPPCT/EP2018/068366T patent/LT3652176T/lt unknown
- 2018-07-06 EP EP18735588.8A patent/EP3652176B1/en active Active
- 2018-07-06 SI SI201830519T patent/SI3652176T1/sl unknown
- 2018-07-06 PT PT187355888T patent/PT3652176T/pt unknown
- 2018-07-06 RS RS20211577A patent/RS62826B1/sr unknown
- 2018-07-06 IL IL271799A patent/IL271799B/en unknown
- 2018-07-06 EA EA202090270A patent/EA039526B1/ru unknown
- 2018-07-06 ES ES18735588T patent/ES2903268T3/es active Active
- 2018-07-06 UA UAA202000735A patent/UA124793C2/uk unknown
- 2018-07-06 CA CA3066922A patent/CA3066922A1/en active Pending
- 2018-07-06 WO PCT/EP2018/068366 patent/WO2019011802A1/en not_active Ceased
- 2018-07-06 HU HUE18735588A patent/HUE057600T2/hu unknown
- 2018-07-06 AU AU2018299824A patent/AU2018299824B2/en active Active
- 2018-07-06 SM SM20220013T patent/SMT202200013T1/it unknown
- 2018-07-06 MY MYPI2019007689A patent/MY200797A/en unknown
- 2018-07-06 SG SG11201912168TA patent/SG11201912168TA/en unknown
- 2018-07-06 MX MX2020000402A patent/MX394089B/es unknown
- 2018-07-10 US US16/031,399 patent/US10329292B2/en active Active
- 2018-07-10 TW TW107123858A patent/TWI801398B/zh active
- 2018-07-11 AR ARP180101931 patent/AR112448A1/es unknown
-
2019
- 2019-12-18 SA SA519410851A patent/SA519410851B1/ar unknown
- 2019-12-30 CO CONC2019/0015102A patent/CO2019015102A2/es unknown
-
2020
- 2020-01-08 CL CL2020000056A patent/CL2020000056A1/es unknown
- 2020-01-10 PH PH12020500079A patent/PH12020500079A1/en unknown
-
2022
- 2022-01-12 CY CY20221100028T patent/CY1125014T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526591A5 (https=) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2007500757A5 (https=) | ||
| HRP20220029T1 (hr) | Supstituirani derivati ksantina | |
| SG10201903475TA (en) | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
| JP2019512528A5 (https=) | ||
| JP2015512418A5 (https=) | ||
| ECSP077852A (es) | Compuestos de espiro-oxindol y sus usos como agentes terapéuticos | |
| EP3483283C0 (en) | METHOD FOR SCREENING AGENTS FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY INTERLEUKIN 6, INTERLEUKIN 13, TNF, G-CSF, CXCL1, CXCL2 OR CXCL5 AND AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY INTERLEUKIN 6, INTERLEUKIN 13, TNF, G-CSF, CXCL1, CXCL2 OR CXCL5 | |
| Hassanzadeh et al. | Effectuality of cognitive-behavioral therapy on the life expectancy of patients with multiple sclerosis | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| JP2024503727A5 (https=) | ||
| Kentner | Neuroprotection and recovery from early-life adversity: considerations for environmental enrichment | |
| JP2022512374A5 (https=) | ||
| WO2020123977A3 (en) | Glial fibrillary acidic protein targeting immuno-and aptamer-based-therapy for neuroinjury, neurodegeneration, neuro-disease, and neuro-repair | |
| Yang et al. | Effect of Chaihu-Shugan-San on the mRNA expression of the 5-HT1A receptor and cellular proliferation in the hippocampus of epileptic rats with depression | |
| Turner et al. | Superficial siderosis associated with anterior horn cell dysfunction | |
| Amini et al. | The Effect of transcranial electrical stimulation on athletic performance optimization: Systematic review, meta-analysis, and proposing a theoretical model | |
| JP2017525776A5 (https=) | ||
| Firouzian et al. | Is ketamine–propofol mixture (ketofol) an appropriate alternative induction agent for electroconvulsive therapy? | |
| JP2020530846A5 (https=) | ||
| MX2023003273A (es) | Ligandos de nlrx1. | |
| Abbruzzese et al. | Rehabilitation of Parkinson’s disease | |
| EP4388098A4 (en) | COMPOSITION COMPRISING AN RNA THERAPEUTIC AGENT TARGETING FAT10 AND USES OF THIS AGENT TO TREAT DISORDERS CHARACTERIZED BY ABNORMAL LIPID ACCUMULATION | |
| RU2016152150A (ru) | Ботулинический токсин для применения в лечении паратонии |